JAK1 and myeloproliferative disorder: Additionally, the reduction in the number of malignant and non-malignant CD11b+Gr-1+ cells elicited by ruxolitinib was not observed for itacitinib (Fig. 7E, F) suggesting that JAK1 inhibition alone does not achieve a relevant therapeutic response in MPN mice.